Beijing Bio-Bank Corporation ("Bio-Bank"), a biopharmaceutical company specializing in large molecule drug development, announced the successful closing of a hundred million RMB Series A financing, led by CDH Investments.

CEC Capital served as the exclusive financial advisor in this transaction for Bio-Bank Corporation.

The proceeds from this round will be primarily used to advance Bio-Bank Corp.'s Platelet-Derived Growth Factor TPG product in Phase II clinical trials in China and the US, as well as the research and development its promising pipeline, including mRNA vaccines.

Established in 2012, Bio-Bank is a national-level high-tech enterprise dedicated to the development of biopharmaceuticals. With a research and development team possessing top-notch expertise in biopharmaceuticals, vaccines, and nanocapsule delivery systems, the company aims to develop biopharmaceutical drugs and vaccines that address significant clinical needs. Bio-Bank's TPG gel formulation, which targets the treatment of diabetic foot ulcers, is a new drug jointly developed by the Academy of Military Medical Sciences and Beijing Bio-Bank Corporation. It is currently undergoing Phase I clinical trials.